Home › NCT07524348

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

A Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Histologically-confirmed, locally advanced (unresectable) or metastatic solid tumors with recurrence or progression during or after standard therapy, intolerance to standard therapy, refused to receive standard therapy, or for whom no standard therapy is available.

Exclusion Criteria:

* Have spinal cord compression or clinically active central nervous system metastases
* Have leptomeningeal disease
* Have thromboembolic or clinically significant bleeding events
* Have significant cardiovascular disease
* Have an active autoimmune disease

About the study

This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

What is being tested

• E303 (drug)

Sponsor: Samsung Bioepis Co., Ltd. · Participants: 149 · Started: Mar 23, 2026

Contact the study team

• Samsung Bioepis · Phone: +82-32-728-0114

Official record on ClinicalTrials.gov — NCT07524348

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.